Form 4: Royalty Pharma Director Acquires Shares Through Restricted Stock Unit Award

Director David C. Hodgson receives 7,614 Class A Ordinary Shares of Royalty Pharma plc through a restricted stock unit award.

Summary

• On May 13, 2025, David C. Hodgson, a director of Royalty Pharma plc, acquired 7,614 Class A Ordinary Shares.
• The acquisition was a result of a restricted stock unit award under the company's 2020 Independent Director Equity Incentive Plan.
• The shares were awarded at a price of $0.
• Following the transaction, Hodgson beneficially owns 33,328 shares.
• The restricted stock units are scheduled to vest 100% on the earlier of (i) the one-year anniversary of the grant date and (ii) the date of the annual meeting of the Issuer's shareholders in the first calendar year following the grant date.
• Hodgson disclaims beneficial ownership of the restricted stock units in the underlying shares, as they are held solely for the benefit of General Atlantic Service Company, L.P.

Sentiment

Score: 7

Explanation: The document reflects a routine transaction related to director compensation, which is generally viewed positively as it aligns interests. There are no indications of negative sentiment.

Positives

• The award of restricted stock units aligns the director's interests with the company's performance.
• The vesting schedule encourages long-term commitment from the director.

Future Outlook

The vesting of the restricted stock units is contingent upon the terms of the 2020 Independent Director Equity Incentive Plan and the applicable award agreement.

Industry Context

Director share acquisitions are common in the pharmaceutical industry as a way to incentivize and align the interests of board members with shareholders.

Comparison to Industry Standards

• Equity compensation for board members is a standard practice across the pharmaceutical industry.
• Companies like Pfizer, Johnson & Johnson, and AbbVie also utilize stock options and restricted stock units as part of their director compensation packages.
• The vesting schedules and terms of these equity grants are typically aligned with industry norms to ensure long-term commitment and performance.

Stakeholder Impact

• The transaction has a minor positive impact on shareholders as it aligns the director's interests with the company's success.

Key Dates

Keywords

Royalty Pharma, Director, Share Acquisition, Restricted Stock Units, RPRX, Beneficial Ownership, Equity Incentive Plan